Submitted by endpointsnews6292 in business
The FDA on Thursday granted accelerated approval to Amgen’s bispecific T cell engager tarlatamab in small cell lung cancer, an aggressive disease that makes up roughly 10% to 15% of lung cancer cases. It’s the first bispecific T cell engager to be approved fo…